Dengue vaccine tetravalent - Sanofi Pasteur

Drug Profile

Dengue vaccine tetravalent - Sanofi Pasteur

Alternative Names: ChimeriVax-Dengue; ChimeriVax™ Tetravalent Dengue Vaccine; ChimeriVax™-DEN1-4; CYD dengue vaccine; Dengvaxia; Live, attenuated, dengue serotype 1, 2, 3, 4 virus vaccine; Tetravalent dengue vaccine

Latest Information Update: 15 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Acambis
  • Developer Sanofi Pasteur
  • Class Attenuated vaccines; Dengue vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Dengue

Most Recent Events

  • 12 Dec 2016 Sanofi plans a phase III trial in Dengue (In children, In adolescents) in Malaysia (NCT02993757)
  • 12 Dec 2016 Sanofi Pasteur plans a phase III trial for Dengue (In adults, In adolescents, In children, Prevention) in Philippines (SC) (NCT02992418)
  • 01 Nov 2016 Sanofi Pasteur initiates enrolment in a phase III trial for Dengue (Prevention, In children, In adolescents) in Mexico (NCT02979535)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top